Vertex Pharmaceuticals (VRTX) Scheduled to Post Earnings on Monday

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) will post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Vertex Pharmaceuticals to post earnings of $3.61 per share for the quarter. Vertex Pharmaceuticals has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion during the quarter, compared to analysts' expectations of $2.50 billion. During the same quarter in the previous year, the company posted $3.33 earnings per share. On average, analysts expect Vertex Pharmaceuticals to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Vertex Pharmaceuticals Price Performance

VRTX stock traded down $1.28 during midday trading on Monday, reaching $396.20. 604,504 shares of the company's stock traded hands, compared to its average volume of 1,220,388. The company has a 50-day simple moving average of $411.08 and a two-hundred day simple moving average of $399.37. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals has a 1-year low of $320.01 and a 1-year high of $448.40. The company has a market cap of $102.40 billion, a price-to-earnings ratio of 28.52, a PEG ratio of 1.87 and a beta of 0.35.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on VRTX. William Blair restated an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 6th. StockNews.com cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 20th. UBS Group reduced their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a "buy" rating on the stock in a report on Wednesday, April 17th. Robert W. Baird cut Vertex Pharmaceuticals from a "neutral" rating to an "underperform" rating and set a $325.00 target price for the company. in a research note on Wednesday, January 31st. Finally, Barclays upped their price target on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $429.45.

Insider Activity

In related news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now directly owns 74,364 shares of the company's stock, valued at approximately $31,250,727.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of the business's stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at $31,250,727.36. The disclosure for this sale can be found here. Insiders have sold 12,381 shares of company stock worth $5,203,249 in the last 90 days. Corporate insiders own 0.20% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.